[1]陈慧,李彬.射血分数中间值心力衰竭的研究进展[J].心血管病学进展,2019,(5):749-752.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.021]
Research progress of heart failure with mid-range ejection fraction[J].Advances in Cardiovascular Diseases,2019,(5):749-752.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.021]
点击复制
射血分数中间值心力衰竭的研究进展(
)
《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]
- 卷:
-
- 期数:
-
2019年5期
- 页码:
-
749-752
- 栏目:
-
综述
- 出版日期:
-
2019-08-25
文章信息/Info
- Title:
-
Research progress of heart failure with mid-range ejection fraction
- 作者:
-
陈慧; 李彬
-
- DOI:
-
10.16806/j.cnki.issn.1004-3934.2019.05.021
- 文献标志码:
-
A
- 摘要:
-
射血分数中间值心力衰竭是区别于射血分数保留的心力衰竭和射血分数降低的心力衰竭的新亚组，其在人口学、病因学、合并症、生物标记物、超声心动图及预后方面均具有介于射血分数保留的心力衰竭和射血分数降低的心力衰竭之间的独特临床特征，而在治疗方面，射血分数中间值心力衰竭患者似乎受益于能够改善射血分数降低的心力衰竭预后的药物治疗，但其获益情况有待进一步证实。现从临床特点、治疗和预后方面对射血分数中间值心力衰竭的研究进展作一综述。
- Abstract:
-
Heart failure with mid-range ejection fraction is a new subgroup distinguishs from heart failure with preserved ejection fraction and heart failure with reduced ejection fraction.It has unique clinical characteristics in demography, etiology, complications, biomarkers, echocardiography and prognosis between heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. In the aspect of treatment, heart failure with mid-range ejection fraction seems to benefit from drug therapy that can improve the prognosis of heart failure with reduced ejection fraction, but the benefits need to be further confirmed. This article reviews the current research progress of heart failure with mid-range ejection fraction in terms of clinical characteristics, treatment and prognosis
更新日期/Last Update:
2019-12-24